Game-Changers and Paradigm Shifts: ASCO 2025 Data Shake Up Breast Cancer Care Podcast Por  arte de portada

Game-Changers and Paradigm Shifts: ASCO 2025 Data Shake Up Breast Cancer Care

Game-Changers and Paradigm Shifts: ASCO 2025 Data Shake Up Breast Cancer Care

Escúchala gratis

Ver detalles del espectáculo

Acerca de esta escucha

From a “game-changer” in triple-negative disease to broader paradigm shifts and practice changes, the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was pivotal for breast cancer care, says Sara M. Tolaney, MD, MPH, chief of the Division of Breast Medical Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts. Dr. Tolaney broke down some of the top data at ASCO 2025 with Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles, California, and Steven Spielberg Family Chair in Hematology-Oncology. She singled out findings from the ASCENT-04 trial, the plenary session on SERENA-6, and the DESTINY-Breast09 trial. “I think it’s been a very exciting ASCO for breast cancer overall, with just so much exciting data,” Dr. Tolaney concluded.

Todavía no hay opiniones